No Data
No Data
Optimistic Outlook for Lexicon Pharmaceuticals: FDA Advances and Strategic Catalysts Poised to Enhance Market Position
Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Lexicon Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 345.43% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/24/2024 345.43% HC Wainwright &
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Joseph Pantginis maintains $Lexicon Pharmaceuticals(LXRX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success
Lexicon Gains as Diabetes Therapy Undergoes FDA Review
Buy Rating Affirmed on Lexicon Pharmaceuticals Amid Promising Sotagliflozin Trials and Upcoming PDUFA Date